Buy ATRA near 7.63 target 12.46 stop loss @ 7.61 Details The technical summary data tells us to buy ATRA near 7.63 with an upside target of 12.46. This data also tells us to set a stop loss @ 7.61 to ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

AstraZeneca has added to its oncology pipeline by licensing a small-molecule KRAS inhibitor from Chinese biotech Usynova for $24 million upfront. The compound – called UA022 – targets the ...

As of 12:32 PM EST. Market Open.

Alternatively, matrix-producing stromal cells are targeted to convert from CAFs to quiescent PSCs with ATRA and from myCAFs to tumor-restraining CAFs with synthetic retinoids. ATRA, all-trans retinoic ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

格索雷塞是由正大天晴与益方生物合作开发的鼠类肉瘤病毒癌基因（KRAS）G12C抑制剂，能够针对KRAS G12C突变进行精准靶向治疗。 2024年11月5日 ...

Average portfolio weight of all funds dedicated to ATRA is 0.01%, an increase of 26.88%. Total shares owned by institutions decreased in the last three months by 9.55% to 2,460K shares.

Financials are currently not available. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.

No major or unexpected toxicities were reported. Pfizer doles out $15M to Cardiff to advance a challenger to Amgen's KRAS winner Lumakras Cardiff’s KRAS-mutated cancer candidate previously ...